| <-- | 1 | 2 | 3 | 4 | 5 | 6 | --> |
10.06.2004
New schizophrenia drug Abilify gets European go-ahead
Thursday , June 10, 2004 (Pharmafocus) Abilify, Bristol-Myers Squibb and Otsuka's antipsychotic has received European Union marketing approval and will be promoted for having fewer side effects than existing treatments, including increased risk of developing diabetes.
more
10.06.2004
Abbott buys heart drug from Aventis for $300 million
Thursday , June 10, 2004 (Pharmafocus) Chicago-based Abbott Laboratories has bought the marketing and manufacturing rights for cardiovascular drug trandolapril from Aventis, in a deal worth $300 million.
more
07.06.2004
Sandoz enters Generic Injectables Field with Acquisition of Sabex
VIENNA, Austria, June 7 /PRNewswire-FirstCall/ -- Sandoz, a Novartis company, today announced plans to acquire Sabex Holdings Ltd. in a USD 565 million cash transaction that will provide strong growth opportunities in injectable generics and new entry into the Canadian generics sector. The deal continues Sandoz strategy of building its global business through strong organic growth and strategic acquisitions that provide access to new geographic markets, therapeutic lines, formulations and production capabilities.
more
06.06.2004
MabThera/Rituxan: 95% Survival Rate In Patients with Aggressive Non-Hodgkin's Lymphoma (NHL)
BASEL, Switzerland and NEW ORLEANS, USA, June 7/PRNewswire/ -- New MabThera(R)/ Rituxan(R) data announced at the American Society of Clinical Oncology (ASCO) Annual Meeting reveal extremely positive survival benefits for younger patients with aggressive non-Hodgkin's lymphoma (NHL). The study showed an overall survival of 95% for those patients who received MabThera (rituximab) in combination with chemotherapy.
more
03.06.2004
Lilly launches first non-stimulant ADHD treatment
Thursday , June 03, 2004 (Pharmafocus) Lilly has launched the first ever non-stimulant ADHD treatment in the UK which it says offers the same relief of symptoms as standard treatment methylphenidate, but without the risk of the drug being abused.
more
02.06.2004
Eloxatin(TM) Based Adjuvant Chemotherapy Provides 23 Percent Reduction in Risk of Colon Cancer Recurrence
PARIS, June 2 /PRNewswire-FirstCall/ -- Results of an ELOXATIN (oxaliplatin for injection) adjuvant trial (MOSAIC) have been published in the current issue of the New England Journal of Medicine. The trial demonstrated that the addition of ELOXATIN(TM) to the current standard of adjuvant chemotherapy for colon cancer (5-fluorouracil/leucovorin known as 5-FU/LV) reduced the risk of recurrence of cancer by 23 percent in patients who had undergone surgical removal of their primary tumor. These are the first results to demonstrate a significant benefit over 5-FU/LV alone, and provide early-stage colon cancer patients with new hope for potential cure of their disease.
more
02.06.2004
Study shows Avastin in Combination with Chemotherapy Improves Survival in all Patient Populations
SOUTH SAN FRANCISCO, Calif. and BASEL, Switzerland, June 2 /PRNewswire-FirstCall/ -- Genentech, Inc. (NYSE:DNA) and Roche (SWX Zurich) today announced that the New England Journal of Medicine published the first Phase III study of an anti-angiogenesis cancer therapy, showing that the addition of Avastin(TM) (bevacizumab) to the IFL chemotherapy regimen (5-FU/Leucovorin/CPT-11) significantly extended survival in patients with first-line (previously untreated) metastatic colorectal cancer.
more
24.05.2004
Sanofi takes charge of arranged marriage
(Pharmafocus) Monday , May 24, 2004 Sanofi-Synthelabo chief executive Jean-Francois Dehecq is preparing his company to merge with larger Franco-German neighbours Aventis to create the world's third biggest pharmaceutical company, and must now deliver the bright future promised for the merged company. After four months of bitter opposition, Aventis was forced to accept an improved offer of E55.3 billion from Sanofi - an arranged marriage orchestrated by a French government unabashed at supporting the deal in favour of Switzerland's Novartis, who had also expressed an interest.
more
17.05.2004
Significant Benefits of FUZEON for Wide Range of Pre-treated HIV/AIDS Patients
BASEL, Switzerland, May 17/PRNewswire/ -- New international consensus guidelines for FUZEON (enfuvirtide) are published today in AIDS, the official journal of the International AIDS Society. These guidelines are vital because they balance the significant benefits of FUZEON with the need for self-injection and also provide a clear framework for FUZEON use.
more
14.05.2004
Zocor approved for sale over-the-counter
Friday , May 14, 2004 (Pharmafocus) The UK government has given the go ahead to the world's first over-the-counter statin drug, Johnson & Johnson MSD 's Zocor Heart Pro (simvastatin) but some doubt whether the move will provide real benefits to patients. Experts on the Committee on Safety of Medicines (CSM) advised the government that the drug should be available without prescription in a 10mg dose in pharmacies across the UK from July.
more
| <-- | 1 | 2 | 3 | 4 | 5 | 6 | --> |
